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Abstract
Cancer stem cell (CSC) based gene expression signatures are associated with prognosis in various tumour types and CSCs
are suggested to be particularly drug resistant. The aim of our study was first, to determine the prognostic significance of
CSC-related gene expression in residual tumour cells of neoadjuvant-treated gastric cancer (GC) patients. Second, we
wished to examine, whether expression alterations between pre- and post-therapeutic tumour samples exist, consistent
with an enrichment of drug resistant tumour cells. The expression of 44 genes was analysed in 63 formalin-fixed, paraffin
embedded tumour specimens with partial tumour regression (10–50% residual tumour) after neoadjuvant chemotherapy
by quantitative real time PCR low-density arrays. A signature of combined GSK3Bhigh, b-catenin (CTNNB1)high and NOTCH2low
expression was strongly correlated with better patient survival (p,0.001). A prognostic relevance of these genes was also
found analysing publically available gene expression data. The expression of 9 genes was compared between pre-
therapeutic biopsies and post-therapeutic resected specimens. A significant post-therapeutic increase in NOTCH2, LGR5 and
POU5F1 expression was found in tumours with different tumour regression grades. No significant alterations were observed
for GSK3B and CTNNB1. Immunohistochemical analysis demonstrated a chemotherapy-associated increase in the intensity of
NOTCH2 staining, but not in the percentage of NOTCH2. Taken together, the GSK3B, CTNNB1 and NOTCH2 expression
signature is a novel, promising prognostic parameter for GC. The results of the differential expression analysis indicate a
prominent role for NOTCH2 and chemotherapy resistance in GC, which seems to be related to an effect of the drugs on
NOTCH2 expression rather than to an enrichment of NOTCH2 expressing tumour cells.
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Introduction
Advanced gastric carcinomas (GC) are frequently treated by
platin/5-fluorouracil (5FU)- based neoadjuvant chemotherapy [1].
The aim of this therapy is, amongst others, to shrink the tumour
before surgery to increase the probability of complete resection
and to thus improve patient survival. However, response rates are
low, and complete or subtotal tumour regression is observed in
only 20–40% of the patients [1,2]. Thus, chemotherapy resistance
is a major obstacle for successful treatment.
According to the cancer stem cell hypothesis, tumour cells are
heterogeneous, and an increased drug resistance is a particular
phenotype of a minority of tumour cells – the so-called cancer-
initiating cells or cancer stem cells (CSCs) [3–5]. An increase in the
CSC population after chemotherapy has been demonstrated [6,7],
and stem cell based gene expression signatures were associated
with poor prognosis in various tumours including gastric
carcinomas [8–11]. The CSC hypothesis is still controversially
discussed, but there is evidence for the existence of CSCs in several
tumour types and molecular markers have been identified which
are preferentially found on these cells [4,5]. The activation of
embryonic signalling pathways, such as the Wnt, Notch and
Hedgehog pathways, has been suggested as a driving force for the
formation of CSCs [4,12]. Data regarding the source and
existence of gastric CSCs remain inconclusive [13–17]. In mice,
bone-marrow derived cells or a specific cell population in the
antrum expressing the Wnt target molecule LGR5, have been
associated with CSCs in the stomach [17,18]. In addition, CD44
and CD24 have been suggested as specific cell surface markers, but
the data are inconsistent [19,20].
The neoadjuvant treatment protocol for GC provides an
excellent opportunity to investigate tumour cells before and after
chemotherapy in patients. In this study, we aimed to elucidate first,
whether the expression of putative CSC-related genes in the post-
therapeutic residual tumour predicts patient survival and second,
whether particular genes are differentially expressed between pre-
therapeutic biopsies and the post-therapeutic tumour specimens,
consistent with an enrichment of chemotherapy-resistant tumour
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cells as predicted by the CSC concept. The group of patients, who
demonstrated considerable tumour shrinkage after neoadjuvant
chemotherapy, but still had sufficient residual tumour cells
available for analysis (10–50% residual tumour) were considered
as the most suitable group to start with a screening analysis for
prognostic relevant genes and to then identify relevant differences
in gene expression between the pre- and post-therapeutic tumour
samples. Analysing these residual tumour cells we identified a gene
expression pattern encompassing GSK3B, CTNNB1 and NOTCH2,
which strongly predicts prognosis of the patients. We show that the
impact of GSK3B and CTNNB1 to this signature is not dependent
on chemotherapy and more likely reflects a property of the
primary tumour and our data further suggest, that in particular
NOTCH2 might play a role for chemotherapy resistance in GC.
Materials and Methods
Patients
In total, 480 patients with locally advanced GC (cT3/4) were
treated by neoadjuvant, platin/5FU-based chemotherapy at the
Department of Surgery at the Technische Universita¨t Mu¨nchen
between 1991 and 2007 and were evaluated for response based on
a standardized histopathological protocol [2–22]. Tumour regres-
sion was classified into 3 grades: tumour regression grade (TRG) 1,
which consists of TRG1a (total tumour regression) and TRG1b
(subtotal tumour regression: ,10% residual tumour cells/tumour
bed), TRG2 (partial tumour regression: 10–50% residual tumour
cells/tumour bed) and TRG3 (minimal or no tumour regression:
.50% residual tumour/tumour bed). Of the 480 patients, 121
patients demonstrated TRG2 and 63 of these were analysed in this
study. The inclusion criterion was the availability of sufficient
tumour tissue for the analysis of patients treated with at least 50%
of the projected dose of chemotherapy. Patient characteristics and
treatment protocols are shown in Table 1. To confirm the
representative nature of the 63 analysed patients, the distribution
of their clinicopathological parameters was compared to the 121-
patient cohort and revealed no statistically significant differences.
Follow-up was calculated from the first day of treatment until
the date of last contact with the patients. The median follow-up
was 77.1 months (range: 28.5–108.5). The clinical endpoint of the
study was overall survival (OS), which was defined as the time
between the first day of chemotherapy and death by any cause.
The median OS was 50.9 months (range: 4.5–108.5, 95% CI:
25.6–76.3), and 37 of the 63 patients died during follow up. This
sample size and number of events are sufficiently large for a
consistent estimation of all effect sizes investigated in this
explorative study [23,24].
The comparison of gene expression between corresponding pre-
and post-therapeutic tumour samples was performed for patients
with TRG2 and TRG3 (each n= 22).
For the immunohistochemical analysis, pre- and post-therapeu-
tic tumour samples from 21 patients with TRG1b, 21 patients with
TRG2, 22 patients with TRG3 and of 16 patients treated by
surgery alone were included. The selection criterion for these
analyses was the availability of corresponding pre-therapeutic
biopsies and post-therapeutic tumours.
Ethics Statement
The study and the use of human tissues was approved by the
local Institutional Review Board at the Technische Universita¨t
Mu¨nchen (reference: 2158/08), and informed consent was
obtained according to institutional regulations.
RNA Extraction and Reverse Transcription
Total RNA was extracted from formalin-fixed, paraffin-
embedded (FFPE) tissues after manual microdissection of tumour
areas composed of at least 50% tumour cells. The RNA was
purified by phenol and chloroform extraction and was reverse
transcribed as described [25].
Gene Expression Analysis
The 44 genes that were selected for analysis based on their
potential role in CSC biology are included in Table 2. Gene
expression was analysed by quantitative real time PCR (qRT-
PCR) on custom-made TaqManH low density arrays (Applied
Biosystems Inc., Foster City, USA). Appropriate reference genes
were determined by an analysis of ten candidate reference genes in
8 gastric carcinomas using the geNorm-algorithm [26]. IPO8,
POLR2A and UBC were determined to be the most suitable
reference genes and normalisation based on the geometric mean of
these three genes was performed as described [26]. Reagents,
Table 1. Patient characteristics and treatment.
Variable Category n (%)
Patients 63 (100)
Age [yrs] median 57.6
range 35.0 – 73.0
Sex female 16 (25)
male 47 (74)
Tumour localisation proximal 43 (68)
medial 12 (19)
distal 7 (11)
total 1 (1)
Lauren classification intestinal 24 (38)
non-intestinal 39 (61)
Tumour grade G1+2 5 (7)
G3 58 (92)
Neoadjuvant
chemotherapy
PLF1 48 (76)
OLF2 3 (4)
Epirubicin-PLF3 4 (6)
Paclitaxel/Docetaxel-PLF4 8 (12)
Resection category R0 53 (84)
R1 10 (15)
ypT category5 ypT0-2 46 (73)
ypT3+4 17 (27)
ypN category5 ypN0 24 (38)
ypN1-3 39 (61)
ypM category5 ypM0 52 (82)
ypM1 11 (17)
1Preoperative chemotherapy protocol: PLF: two cycles, each consisting of
cisplatin (50 mg/m2 body surface area (BSA)) at weeks 1, 3 and 5, and both
leucovorin (500 mg/m2 BSA) and 5-fluorouracil (2000 mg/m2 BSA) at weeks 1, 2,
3, 4, 5 and 6 (PLF),
2Oxaliplatin (85 mg/m2 BSA) replaces cisplatin in PLF.
3Additional epirubicin (30 mg/m2 BSA) at weeks 2, 4, and 6,
4Additonal paclitaxel (85 mg/m2 BSA) or docetaxel (40–50 mg/m2 BSA) at
weeks 1, 3, and 5,
5TNM Classification of Malignant Tumors, 6th Edition, UICC.
doi:10.1371/journal.pone.0044566.t001
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cycling conditions and software are included in the Supporting
Information. Relative gene expression was quantified using the
comparative DDCt method [27].
Immunohistochemistry
The monoclonal NOTCH2 antibody (C651.6DbHN) was
obtained from the Developmental Studies Hybridoma Bank
(DSHB, The University of Iowa, Department of Biology, Iowa
City, USA). The staining procedure and examination of antibody
specificity by Western blotting are described in the Supporting
Information and Figure S1A.
Immunohistochemical staining was scored in a blinded fashion
by two independent researchers (L.B. and R.L). Cytoplasmic and
nuclear staining was evaluated separately. Negative, weak,
medium or strong staining intensities were scored as 0, 1, 2 and
3, respectively. The percentage of tumour cells with stained
cytoplasm/nucleus was scored as 0 (negative), 1 (,10%), 2 (10 to
,50%), 3 (50 to ,80%) and 4 ($80%).
Statistical Analysis
Conditional inference tests were used to determine the optimal
cut-off-values of gene expression for the association with patient
survival and to determine the p-values appropriate for maximally
selected statistics [28]. Gene expression values above or equal to
the optimal cut-off value were defined as high expression and gene
expression values below the cut-off value were defined as low
expression. Survival rates were estimated according to Kaplan-
Meier curves and were compared by log-rank tests. Relative risks
were estimated by determining hazard ratios (HRs) from Cox
proportional hazard models. In the multivariate analysis, stepwise
forward variable selection was performed based on likelihood ratio
tests. The ratio of the number of variables in the model to the
number of events was limited to 1:10 [24].
Comparisons of clinicopathological variables between groups
were performed by Mann-Whitney-U tests. The x2-test and
Fisher’s exact test were used for the comparison of relative
frequencies where appropriate. Statistical differences of gene
expressions between paired samples were analysed using the
Wilcoxon signed rank test.
Unsupervised hierarchical cluster analysis was performed with
Cluster 3.0 software [29] and Java TreeView software (version
1.1.5r2) [30]. Relative mRNA expression data were log-trans-
formed, median-centred and normalised before applying complete
linkage clustering with a distance matrix based on Pearson’s
correlation (uncentred).
A risk score was calculated by summarizing the products of the
multiplication of the Cox regression coefficient of each gene in the
model with the normalised gene expression values for each patient
essentially as described [31] (details in Material and Methods S1
and Tables S4 and S6).
All statistical tests were two-sided and conducted in an
explorative manner with a significance level of 0.05 using the
SPSS 18.0 software (SPSS Inc., Chicago, IL 11.5) and R (R
Foundation for Statistical Computing, Vienna, Austria).
The study complies with the reporting recommendations for
tumour marker prognostic studies (REMARK criteria) [32].
Analysis of Public Microarray Data
Publically available gene expression array data of gastric
carcinomas with descriptions of clinical characteristics and patient
survival [33] were obtained from the BRB-Array Tools data
archive (http://linus.nci.nih.gov/˜brb/DataArchive_New.html)
and analysed using BRB-Array Tools [34] (Supporting Informa-
tion). Only advanced gastric carcinomas (T3/4) (n = 58) were
Table 2. Genes analysed by TaqManH low density array.
Gene Gene ID1 AssayID2
Amplicon-length
[bp]
ABCB1 5243 Hs00184500_m1 67
ABCG2 9429 Hs01053790_m1 83
ALDH1A1 216 Hs00946916_m1 61
ASCL2 430 Hs00270888_s1 101
ATXN1 6310 Hs00165656_m1 97
AXIN1 8312 Hs00394718_m1 81
BMI1 648 Hs00180411_m1 105
CCND1 595 Hs00765553_m1 57
CD133 8842 Hs01009257_m1 80
CD24 100133941 Hs02379687_s1 140
CD34 947 Hs02576480_m1 63
CD44 960 Hs01075861_m1 70
CDH1 999 Hs01013953_m1 65
CDX2 1045 Hs01078080_m1 81
CHD1 1105 Hs00154405_m1 84
CTNNB1 1499 Hs00355045_m1 86
DKK3 27122 Hs00247426_m1 83
DNMT1 1786 Hs00154749_m1 77
DNMT3A 1788 Hs01027166_m1 79
DNMT3B 1789 Hs00171876_m1 55
FOXD3 27022 Hs00255287_s1 73
FZD1 8321 Hs00268943_s1 83
GADD45A 1647 Hs00169255_m1 123
GLI1 2735 Hs00171790_m1 80
GSK3B 2932 Hs00275656_m1 73
HDAC1 3065 Hs00606262_g1 149
HDAC2 3066 Hs00231032_m1 106
IHH 3549 Hs01081801_m1 103
KLF4 9314 Hs00358836_m1 110
LGR4 55366 Hs00173908_m1 68
LGR5 8549 Hs00173664_m1 112
LIN28 79727 Hs00702808_s1 143
MKI67 4288 Hs01032443_m1 66
MYC 4609 Hs00905030_m1 87
NANOG 79923 Hs02387400_g1 109
NOTCH1 4851 Hs01062014_m1 80
NOTCH2 4853 Hs01050719_m1 60
OLFM4 10562 Hs00197437_m1 85
POU5F1 5460 Hs00999632_g1 77
PTCH1 5727 Hs00970979_m1 63
SFRP1 6422 Hs00610060_m1 130
SHH 6469 Hs00179843_m1 70
SMO 6608 Hs01090242_m1 54
SOX2 6657 Hs01053049_s1 91
IPO83 10526 Hs00183533_m1 71
POLR2A3 5430 Hs00172187_m1 61
UBC3 7316 Hs00824723_m1 71
1www.ncbi.nlm.nih.gov/gene,
2Applied Biosystems,
3Reference genes.
doi:10.1371/journal.pone.0044566.t002
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included in the analysis. The optimal cut-off values of GSK3B,
CTNNB1, and NOTCH2 expression were determined for an
association with patient survival by the conditional inference tests
for maximally selected statistics as described above.
Results
Gene Expression and Patient Survival
The gene expression profiling of the 63 tumours of patients with
TRG2 showed, that high expression levels of GSK3B, DNMT1 and
CTNNB1 were significantly associated with better survival
(conditional inference test: p = 0.006, 0.041, and 0.043, respec-
tively). A moderate association with better survival was observed
for high expression of ABCG2 and OLFM4 (p = 0.051, p= 0.055)
and for low expression of NOTCH2 (p = 0.071) (Table 3).
Univariate Cox-regression analysis demonstrated approximately
concordant results (Table 4).
A multivariate Cox regression analysis including GSK3B,
CTNNB1, DNMT1 and the standard prognostic variables in GC,
namely ypT, ypN, ypM and resection category revealed GSK3B as
the second most important independent prognostic factor (HR:
0.128, 95% CI: 0.033–0.492, p = 0.003) after distant metastasis
(Table S1).
A cluster analysis encompassing all of the analysed genes
revealed no patient groups that exhibited an association with OS.
A cluster analysis of Wnt- and Notch signalling-associated genes
produced the most significant association with OS when GSK3B,
CTNNB1 and NOTCH2 were included (p = 0.002) (Figure 1A and
B). According to the results of the cluster analysis, we grouped the
patients into three groups with different combinations of high or
low expression of GSK3B, CTNNB1 and NOTCH2, which was
defined by the optimal cut-off-values for gene expression in
association with patient survival. The group with GSK3Bhigh,
CTNNB1high and NOTCH2low expression showed the best survival,
whereas the group with GSK3Blow, CTNNB1low and NOTCH2high
expression had the worst overall outcome (p,0.001, Figure 1C).
Calculation of a risk score based on a multivariate Cox
proportional hazard regression model of these three genes and
dichotomisation of the patients according to the optimal cut-off
value for OS into a high (n= 37) and low (n= 26) risk group
demonstrated a statistically significant difference for OS (median
survival of low and high risk patients: not reached and 37 months
respectively; p,0.001). In addition, the difference in the respective
survival rates at 1, 2, 3 and 5 years between the low and high risk
group were statistically significant (Table S5).
Differential Gene Expression Analysis between
Corresponding Pre- and Post-therapeutic Tumour
Samples
We next determined, whether the expression levels of the genes
that exhibited a significant or moderate association with OS
(p,0.1, Table 3 and 4) differ between pre-therapeutic biopsies and
their corresponding post-therapeutic tumour specimen. Addition-
ally, POU5F1, LGR5 and CCND1 were analysed, and tumour
samples of patients with TRG2 or TRG3 (each n= 22) were
studied.
In patients with TRG2, the expression of NOTCH2, POU5F1
and LGR5 increased significantly between the pre- and the post-
therapeutic specimens (p = 0.002, 0.028 and 0.017, respectively)
and the expression of DNMT1 decreased (p= 0.009). In the group
with TRG3, POU5F1 exhibited a significant increase (p = 0.002),
while DNMT1 and CCND1 significantly decreased (p = 0.002 and
0.007, respectively).
Regarding the expression of the prognostic-relevant genes
GSK3B and CTNNB1, no statistically significant differences were
observed between the pre- and the post-therapeutic tumour
samples (Table 5 and Tables S2 and S3).
Analysis of Publically Available Array Data
To evaluate the general prognostic value of the GSK3Bhigh,
CTNNB1high and NOTCH2low expression pattern, we used a
publically available expression array data set of gastric carcinomas
[33]. The data set included the genes of interest and the relevant
clinical information (OS, tumour stage) necessary to perform an
analogous analysis. The determination of the optimal cut-off
values of gene expression for correlation with survival and
evaluation of the combined expression signature of GSK3Bhigh,
CTNNB1high and NOTCH2low identified a group of 10 patients
who had a significantly longer OS (p = 0.017, median OS: not
reached) compared with the 47 remaining patients (median OS:
14.0 mo, 95% CI: 8.7–19.4) (Figure 1D).
Calculation of the risk score for this patient group and
dichotomisation of the patients according to the optimal cut-off
value for OS showed a considerably longer OS for the low risk
group (n= 27) compared to the high risk group (n= 30), although
the difference was not statistically significant (median survival 21
versus 13 months, p = 0.110). Considering the differences in the
respective survival rates at 1, 2 and 3 years demonstrated
analogous results with the most obvious difference at 2 years with
a survival rate of 45% of the low risk patients and 21% of the high
risk patients (p = 0.071) (Table S7).
Immunohistochemical Analysis of NOTCH2
To evaluate the differences in gene expression between the
paired pre- and post-therapeutic tumours on the protein level, we
performed immunohistochemistry and focused on NOTCH2
(Figure S1B and C). We analysed the same patient groups that
had been studied on the mRNA level. In addition, 21 patients with
TRG1b and a control group of 16 patients treated by surgery
alone were included.
A comparison of cytoplasmic staining intensities between pre-
therapeutic biopsies and their corresponding post-therapeutic
tumours revealed a statistically significant increase in staining
intensity in the post-therapeutic specimens from patients with
TRG1b, 2 and 3 (p = 0.016, 0.001, and 0.017, respectively). In
contrast, no differences were observed in patients treated by
surgery alone (p= 0.438) (Figure 2). The percentage of stained cells
was not significantly altered. Regarding nuclear staining, a
significant decrease in staining intensity in the post-therapeutic
Table 3. Gene expression and association with survival –
conditional inference tests.
, cut-off $ cut-off
Gene n
median survival
[mo] n
median survival
[mo] p-value
GSK3B 40 47.1 23 102.6 0.006
DNMT1 53 42.1 10 nr 0.041
CTNNB1 15 32.3 48 94.9 0.043
ABCG2 54 47.1 9 102.6 0.051
OLFM4 53 40.4 10 nr 0.055
NOTCH2 31 94.9 32 40.4 0.071
nr: median survival not reached.
doi:10.1371/journal.pone.0044566.t003
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tumour specimen was found in the group with TRG2 (p= 0.007),
TRG3 (p = 0.015) and in the control group not treated by
chemotherapy (p = 0.016). A significant decrease in the percentage
of cells with stained nuclei was observed in the group with TRG1b
(p = 0.005), TRG2 (p,0.001), TRG3 (p= 0.003) as well as in the
control group (p= 0.001).
Discussion
Our study analysing the expression of CSC related genes in
residual gastric cancer cells after neoadjuvant chemotherapy
identified a gene signature with a high prognostic impact
composed of GSK3B, the b-catenin gene CTNNB1 and NOTCH2.
Interestingly, high expression levels of CTNNB1 and GSK3B were
associated with increased survival. B-catenin is a key molecule in
the transmission of Wnt signalling to the nucleus and drives
multiple cellular processes [35]. Aberrant Wnt signalling has been
demonstrated in up to 46% of GCs, and both Wnt/b-catenin and
proliferation/stem cell expression signatures indicating the respec-
tive pathway activation, were associated with decreased patient
survival [36]. CTNNB1 mRNA levels can modulate Wnt signalling
[37], and Wnt activity has been linked to cancer stemness in the
colon [38]. Given these data, a negative association of CTNNB1
expression in residual tumour cells after chemotherapy and the
survival of the patients would have been expected. However, b-
catenin is also part of the E-cadherin-catenin complex and
alterations in this cell adhesion complex have been associated with
worse prognosis in various tumours [39]. In GC, conflicting results
regarding the association between b-catenin expression and
patient prognosis exist [40,41].
It is important to note, that GSK3B is also a multifunctional
protein involved in various signalling networks and antagonises
Wnt signalling by mediating the degradation of b-catenin,
although a Wnt-activating function has also been described [42–
44]. Increased expression of GSK3B was associated with a
favourable prognosis in our study, which is consistent with a
report of higher GSK3B mRNA expression associated with better
survival in ovarian high-grade serous carcinomas [45].
Higher NOTCH2 expression levels correlated with worse
survival in our GC patients. The Notch receptor family
encompasses four members, and NOTCH1 and NOTCH2 have
been implicated to enhance gastric cancer progression [46,47].
Furthermore, an association of NOTCH1 expression with poor
prognosis has been reported [48], which is not consistent with our
findings; however, due to the differences in the study populations,
these results are not directly comparable.
Given the highly significant association of the gene signature
encompassing CTNNB1, GSK3B and NOTCH2 with patient
survival and the significant risk score–based classification of the
patients into a high and low risk group, we were particularly
interested, if this were related to chemotherapy. The comparison
of GSK3B and CTNNB1 expression levels between pre- and post-
therapeutic tumour samples revealed no clear differences, whereas
a significant increase in the expression of NOTCH2 was found.
This finding suggests that CTNNB1 and GSK3B expression may
reflect a property of the primary tumour that is not altered by
chemotherapy and that NOTCH2 expression in the residual
tumour cells is at least partly related to this treatment.
An analysis of the prognostic significance of the three-genes in
publically available genome-wide expression data of advanced GC
demonstrated a significant association for the specific gene
expression pattern of GSK3Bhigh, CTNNB1high and NOTCH2low
expression and increased patient survival and a similar tendency
considering the risk score-based classification.
Figure 1. Expression of GSK3B, CTNNB1 and NOTCH2 and association with survival. A) Clustering of tumours based on expression of GSK3B,
CTNNB1 and NOTCH2. B) The Kaplan-Meier curves of the patient clusters show better survival of patients in cluster 2 (median OS not reached)
compared to cluster 1 (median OS 36.7 mo, 95% CI 24.4–49.1) or cluster 3 (median OS 55.9 mo, 95% CI 16.7–95.0). C) Kaplan-Meier curves of patients
based on the categorisation of tumours according to the optimal cut-off values for the three genes (GSK3Bhigh CTNNB1high NOTCH2low: median OS not
reached; GSK3Blow CTNNB1low NOTCH2high: median OS 18.0 mo, 95% CI 0–39.5; Others: median OS 42.1 mo, 95% CI 28.3–55.9). D) Analysis of
publically available array data of gastric cancer [32]. Kaplan-Meier curves of patients categorised according to the combined expression of GSK3B,
CTNNB1 and NOTCH2 in the tumours using optimal cut-off values are shown (GSK3Bhigh CTNNB1high NOTCH2low: median OS not reached; Others:
median OS 14.6 mo, 95% CI 8.6–19.3). P-values were determined by the log-rank test.
doi:10.1371/journal.pone.0044566.g001
Table 4. Gene expression and association with survival –
univariate Cox regression analysis.
Gene HR1 95% CI2 p-value
GSK3B 0.220 0.064–0.756 0.016
DNMT1 0.379 0.138–1.042 0.060
CTNNB1 0.567 0.305–1.052 0.072
ABCG2 0.851 0.707–1.024 0.087
OLFM4 0.987 0.969–1.006 0.191
NOTCH2 3.326 0.935–11.840 0.064
1hazard ratio,
295% confidence interval.
doi:10.1371/journal.pone.0044566.t004
Table 5. Alterations of expression between pre- and post-
therapeutic tumours of patients with tumour regression grade
(TRG) 2 and 3.
TRG2 TRG3
Alteration Gene p-value1 Gene p-value1
Increase
NOTCH2 0.002 NOTCH2 0.062
POU5F1 0.028 POU5F1 0.002
LGR5 0.017
CTNNB1 0.062
No change
ABCG2 0.263 LGR5 0.249
GSK3B 0.263 CTNNB1 0.733
OLFM4 0.211 ABCG2 0.485
CCND1 0.178 GSK3B 0.709
OLFM4 0.961
Decrease
DNMT1 0.009 CCND1 0.007
DNMT1 0.002
1Wilcoxon signed rank test.
doi:10.1371/journal.pone.0044566.t005
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This finding supports the interpretation that the prognostic
effect observed in our study mainly reflects a property of the
primary gastric tumour, suggesting a critical role for these genes in
the biology of these tumours. In addition, the prognostic effect
observed might be enhanced by an increase in the expression of
NOTCH2 in the residual tumour after chemotherapy. Thus, if
validated in a prospective study, this three gene signature might be
useful for risk stratification of GC patients and additionally may
guide postoperative treatment after neoadjuvant chemotherapy.
Our results are reminiscent of a recent study analysing a CSC-
derived gene signature that predicts tumour recurrence in the
colon and demonstrates that the elevated expression of Wnt target
genes is indicative of a favourable prognosis [48]. The authors
provide evidence that this association more likely reflects the
differentiation status of the malignant tissue rather than the
number of CSCs [49].
In considering the alterations of NOTCH2 expression between
corresponding pre- and post-therapeutic tumours, it is important
to note that comparing gene expression at the mRNA-level,
cannot distinguish whether these alterations reflect a relative
enrichment of the cells expressing this gene, whether they are due
to the chemotherapeutic agents affecting gene transcription in the
cells per se, or whether the alterations reflect mere sampling
differences. To clarify this issue we analysed NOTCH2 protein
expression by immunohistochemistry and included tumours from
patients treated by surgery alone. Based on the cytoplasmic
staining, our results confirm an increase in NOTCH2 expression
at the protein level in the post-therapeutic tumours and they
demonstrate that the observed differences are likely to be restricted
to patients treated by chemotherapy. Of note, the increase in
NOTCH2 expression was related to an increase in the cytoplasmic
staining intensity rather than to an increase in the number of cells
expressing NOTCH2. This result argues against an enrichment of
a subpopulation of NOTCH2-expressing tumour cells and more
likely suggests a chemotherapy-induced increase in gene expres-
sion in the tumour cells, which may be related to the tumour
biological features after neoadjuvant treatment. However, a clear
distinction between these possibilities may be limited by the
semiquantitative evaluation of immunohistochemical staining. As
similar alterations in nuclear staining were observed in all tumour
groups including the control we considered these changes as
unrelated to chemotherapy.
Irrespective of the mechanism and the true nature of the
residual tumour cells expressing NOTCH2, our results may have
therapeutic implications. Notch signalling has emerged as a
potential new therapeutic target, and gamma-secretase inhibitors,
which inhibit the processing of the Notch receptors, are currently
being evaluated in clinical trials [50]. Our study suggests that
targeting Notch signalling may also represent a new strategy to
treat GC patients. As an adverse prognostic effect was only
associated with NOTCH2 and not NOTCH1, our data also indicate
that a detailed characterisation of the individual Notch receptors
and a thorough functional investigation are mandatory and further
strongly favour the development of Notch paralog-specific
inhibitory agents.
A significant increase in POU5F1 expression was observed after
chemotherapy in the resected specimens in our study. The
POU5F1 transcription factor is essential for the maintenance of
self-renewal, and its high expression in residual cancer cells after
radiochemotherapy is correlated with poor prognosis in colon
cancer [51]. Interestingly we also observed an increased expression
of LGR5, a promising intestinal CSC marker, after chemotherapy
in tumours with TRG2 [18]. These results are compatible with the
potential enrichment of drug-resistant tumour cells expressing
POU5F1 or LGR5, but the underlying mechanism for these
alterations and the particular properties of the cells expressing
these genes remain to be determined.
In our study, no association with survival were observed for the
cell surface molecules CD44 or CD133, both of which have been
widely used to identify putative CSCs in various tumours [4–11].
This result supports recent findings demonstrating that these cell
surface molecules do not identify CSCs in primary gastric tumours
[20].
Taken together, our findings demonstrate that the expression
signature of GSK3Bhigh, CTNNB1high and NOTCH2low in chemo-
therapy-resistant residual GC tumour cells is a strong predictor for
favourable patient prognosis. This prognostic relevance was also
demonstrated for GC patients using publically available gene
expression data. The results of the differential expression analysis
of the pre- and post-therapeutic tumour specimen also suggests
that the impact of GSK3B and CTNNB1 to this signature is not
dependent on chemotherapy but rather related to a property of the
primary tumour. They further indicate a prominent role for
NOTCH2 and chemotherapy resistance in GC, which is more
likely related to an effect of the chemotherapeutic agents on
NOTCH2 expression rather than to an enrichment of NOTCH2
expressing tumour cells.
Figure 2. Alterations in the immunohistochemical staining for NOTCH2 between pre-therapeutic biopsies and their corresponding
post-therapeutic tumours. Alterations of cytoplasmic staining intensities are shown. Each line indicates the alteration of the immunohisto-
chemical staining score between the pre-therapeutic biopsy (Pre) and the corresponding post-therapeutic tumour specimen (Post) for each case. P-
values were determined by the Wilcoxon signed rank test (exact).
doi:10.1371/journal.pone.0044566.g002
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Supporting Information
Figure S1 Western blot and immunohistochemistry with the
anti-NOTCH2 antibody. A) The antibody directed against the
NOTCH2 intracellular domain specifically detects the full length
NOTCH2 protein above the 250 kDa marker as well as the
cleaved forms NOTCH Extracellular Truncated (NEXT) and
NOTCH Intracellular Domain (NICD) at approximately
110 kDa. B) A weak cytoplasmic immunohistochemical staining
in the pre-therapeutic biopsy sample and C) a strong cytoplasmic
staining in the corresponding post-therapeutic tumour with TRG2
is shown. Scale bars indicate 50 mm.
(TIF)
Table S1 Multivariate Cox regression analysis. Gene expression
of GSK3B, CTNNB1, DNMT1 and the standard prognostic
variables in GC, ypT, ypN, ypM and resection category were
included in the model.
(DOC)
Table S2 Gene expression data of the pre- and corresponding
post-therapeutic tumour samples of patients with TRG2.
(DOC)
Table S3 Gene expression data of the pre- and corresponding
post-therapeutic tumour samples of patients with TRG3.
(DOC)
Table S4 Multivariate Cox regression data for the own dataset.
(DOC)
Table S5 Relative survival rates based on the dichotomised risk
score (own data).
(DOC)
Table S6 Multivariate Cox regression data for the publically
available dataset.
(DOC)
Table S7 Relative survival rates based on the dichotomised risk
score (public data).
(DOC)
Material and Methods S1 Information on experimental details
on quantitative real time PCR, immunohistochemistry, Western
blotting, the analysis of public microarray data and multivariate
Cox regression based risk scores.
(DOC)
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